Lyell Immunopharma, Inc.LYEL
Market cap
$10.4B
P/E ratio
| Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Revenue | 11 | 85 | 0 | 0 |
| Research and development | - | - | - | 172 |
| General and administrative | 89 | 117 | 67 | 52 |
| Other operating income, net | 2 | 5 | 3 | 3 |
| Acquired in-process research and development | - | - | - | 87 |
| Impairment of long-lived assets | - | - | - | 51 |
| Total operating expenses | 225 | 272 | 247 | 359 |
| Loss from operations | -215 | -187 | -247 | -359 |
| Interest income, net | 1 | 7 | 23 | 24 |
| Other income, net | -0 | 2 | 2 | 5 |
| Impairment of other investments | - | 5 | 13 | 13 |
| Total other income, net | -35 | 4 | 12 | 16 |
| Net loss | -250 | -183 | -235 | -343 |
| Net unrealized gain (loss) on marketable securities | -2 | -6 | 8 | 0 |
| Comprehensive loss | -252 | -189 | -227 | -343 |
| Earnings Per Share, Basic | -1.84 | -0.74 | -0.93 | -1.31 |
| Earnings Per Share, Diluted | -1.84 | -0.74 | -0.93 | -1.31 |